James Campbell was appointed Non-Executive Director of Prescient Therapeutics in 2014. Dr Campbell has a demonstrable track record as both a scientist and commercial executive in the sector. He was previously CFO and Chief Operating Officer of Chemgenex which was acquired by Cephalon for 230 million in 2011. At ChemGenex his responsibilities ranged from intellectual property management to licensing and business development. More recently Dr Campbell guided the creation of Invion Limited as an Executive Director and remains a Non-Executive Director of that Company. He has also assisted private biotechnology companies in New Zealand and the US with capital raising and partnering negotiations. Dr Campbell is also a Non-Executive Director of BioProspect Limited and Patrys Limited .